| Sep 3 |
ProKidney revises Phase 3 program for lead asset
|
| Sep 3 |
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
|
| Aug 27 |
ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 23 |
The Prognosis For ProKidney: Unclear
|
| Aug 9 |
ProKidney GAAP EPS of -$0.16
|
| Aug 9 |
ProKidney Reports Business Updates and Second Quarter 2024 Financial Results
|
| Jul 30 |
ProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutions
|
| Jun 17 |
ProKidney Announces the Closing of $140 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering, Including Exercise of Underwriters’ Option
|
| Jun 12 |
ProKidney surges 18% following pricing of upsized $130M stock offering
|
| Jun 12 |
ProKidney prices upsized stock offering to raise $130 million
|
